FDA Breakthrough Therapy Designation for Alnylam’s RNAi Drug Givosiran

Alnylam Pharmaceutical (ALNY) calls RNAi (RNA interference) a revolution in biology. The FDA’s just granted the firm’s RNAi therapy breakthrough for a disease nobody has ever dreamed of conquering confirms this reality in spite of spending years of efforts and money towards turning the RNAi molecules into therapeutic molecules that can be used safely and effectively. RNAi-related treatments represent a completely new approach to drug discovery and development. “Its discovery has been heralded as a major scientific breakthrough that happens once every decade or so”.

The approach represents one of the most promising among the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.